Fibreoptic intubation remains an essential skill for anaesthetists to master. In addition to the reusable fibrescope, an alternative disposable videoscope is available (aScope™2, Ambu®, Ballerup, Denmark). A total of 60 anaesthetised adult patients were randomised to either having orotracheal intubation using the aScope 2 or a Karl Storz fibrescope. Intubations were performed by experienced operators who were familiar with both devices. The primary outcome was the Global Rating Scale score. Secondary outcomes included intubation success, number of intubation attempts and intubation time. Other subjective outcomes including practicality, useability and image quality were also recorded. There was no significant difference in the Global Rating Scale score, intubation success or intubation time between the aScope 2 or Karl Storz fibrescope. Global Rating Scale scores were three and two in the aScope 2 and Karl Storz groups respectively (P=0.14). All of the other subjective outcomes were similar between the two groups, except that operators found it easier to use the aScope 2 compared to the fibrescope. There was no significant difference in clinical performance between the aScope 2 and the Karl Storz fibreoptic bronchoscope. The aScope's practicality, disposability and recently improved version (aScope™3) potentially make it an acceptable alternative to the reusable fibrescope.
Despite recent advances in equipment for managing difficult airways, difficult airway management remains a leading cause of devastating adverse outcomes in anaesthesia 1 . Fibrescope-guided tracheal tube placement remains a useful technique for the management of the predicted and unpredicted difficult airway. This skill is fundamental for every practising anaesthetist, yet remains one of the hardest to acquire and maintain even with consistent practise 2 . Until recently, we have relied on reusable fibrescopes for this purpose. A disposable alternative, the aScope™ 2 (Ambu®, Ballerup, Denmark) has been available since 2010. The aScope 2 is a single-use flexible videoscope designed for fibreoptic tracheal intubation. The manufacturers cite the elimination of risk of cross infection, quick and convenient device setup and cost as key benefits for using the device 3 . A case series published by Pujol et al supports this, but also highlights key weaknesses being the absence of a suction channel and lower image resolution 4 . The aScope 2 has now been superseded by the aScope 3 standard and aScope 3 slim. Key improvements include improved image resolution and the introduction of a suction channel.
Evaluation of the aScope 2, as well as comparison with the fibreoptic bronchoscope, has been performed in manikins [5] [6] [7] . However, there are limited clinical trials available. The aim of our clinical study is to compare the aScope 2 with a standard reusable fibrescope in performing orotracheal intubation in anaesthetised adult patients. We hypothesise that using the aScope 2 would achieve a better Global Rating Scale score (GRSs) when compared to the standard fibrescope 8, 9 . We would also assess the practicality of using the aScope 2 in the clinical setting.
Methods
After obtaining approval from the Melbourne Health Human Research Ethics Committee (MH Project Number: 2011.079) and registration from the Australian New Zealand Clinical Trials Registry (Registry No.: 12611001235998), a total of 60 adult patients scheduled for elective surgery requiring orotracheal intubation at the Royal Melbourne Hospital were recruited. Patients who required an awake fibreoptic intubation, inhalational induction, known difficult/ impossible mask ventilation/intubation and those requiring rapid sequence induction were not included.
After obtaining written informed consent, each patient was randomly allocated to either the aScope2 or Karl Storz flexible reusable fibreoptic bronchoscope (Karl Storz GmbH & Co. KG, Tuttlingen, Germany) study group. The characteristics of the two devices are summarised in Table 1. Each allocation was achieved using a computer-generated randomisation method. The patient allocation was put in individually numbered and sealed opaque envelopes before recruitment. The person responsible for recruitment was unaware of the allocation result. The allocation was revealed only after patient consent was obtained for the study.
The operator who was assigned to the task of performing scope-assisted intubation was selected from a pool of experienced specialist anaesthetists. All of the operators were briefed on the use of the aScope 2 and were exposed to the trainer version of the aScope 2 in an airway manikin (Airsim Multi Manikin, Trucorp, Belfast, Ireland). They were also familiar with the Karl Storz reusable fibreoptic bronchoscope, which was used frequently within the department for both elective and emergency fibreoptic intubation. There was also a two-hour formal practice session with both the Karl Storz bronchoscope and aScope 2 prior to commencement of the trial.
Recording of the aScope 2 intubation attempts were performed using a PC-based setup with a netbook, USB video capture device, composite video output cable and video capture software. Video output signals from the aScope monitor were then recorded on the PC. The recording setup of the Karl Storz fibrescope was similar to the aScope's setup. A camera was attached to the eyepiece of the fibrescope and connected to a 12-inch colour LCD monitor (Tele Pack®, Karl Storz GmbH & Co. KG, Tuttlingen, Germany). The video output came from an S-video cable from the Karl Storz Telepak monitor.
All video clips were saved in the same format on the computer and de-identified for later assessment. Two blinded investigators independently evaluated the video clips, which recorded the intubation process as shown on the aScope 2 or fibrescope monitor screen. The camera view was from the tip of the scope. Therefore, the identity of the scope could not be determined from the video clips.
The patient's baseline characteristics and intubation operators' characteristics were collected preoperatively. All patients received a standardised relaxant general anaesthetic by the treating anaesthetist, in accordance with ANZCA guidelines. Glycopyrrolate 200 μg IV was administered 30 minutes prior to induction of anaesthesia for its antisialogogue effect. Pre-oxygenation was performed by facemask for three to five minutes to obtain an endexpiratory oxygen concentration of >70%. Induction of anaesthesia was then commenced with drugs of the treating anaesthetist's choice. Mask ventilation of the patient was performed with 100% oxygen until complete paralysis was achieved. A train-of-four count of zero using a peripheral nerve stimulator was taken as complete paralysis. Depending on the randomisation, intubation was performed with either the aScope 2 or the Karl Storz fibrescope. The designated flexible scope was lubricated and preloaded with an appropriately sized tracheal tube (Mallinckrodt Hi-Contour Oral Tracheal Tube Cuffed, Covidien, Dublin, Ireland). Low flow oxygen was insufflated down the Luer lock channel of the aScope 2 or the suction port of the fibrescope. The flexible scope was inserted orally and directed into the trachea with jaw thrust applied to the patient until the carina was visualised. The tracheal tube was railroaded over the scope into the trachea and the flexible scope was then withdrawn and visual confirmation of intubation was verified.
The primary outcome was the GRSs (see Appendix 1), which was assessed from the videoclips by two blinded independent observers. These observers also recorded the intubation times (T1=time to identify carina, which was defined as time from scope insertion past the front teeth to identification of carina; T2=total intubation time, which was defined as time from scope insertion past the front teeth to visual confirmation of tracheal tube within the trachea) from the videoclips. Other secondary outcomes were collected by an independent observer during the time of intubation. These included intubation success (tracheal intubation was considered failed if it could not be accomplished within two attempts) and number of intubation attempts (intubation attempt was defined as insertion of the scope into the patient's mouth). Other subjective outcomes, including ease of use, ease of setup, manoeuvrability of the scope, image quality and ease of railroading tracheal tube, were assessed via direct questioning of the intubating anaesthetist using the verbal rating score (1=best, 5=worst).
Statistical analysis
Sample size calculations were performed using G Power 3.0. 8 
Results
The baseline characteristics of the patients and operators were similar in both groups (Table 2 ). There were no significant differences in the GRSs between the two groups. Although the number of intubation attempts was lower in the aScope 2 group compared to the fibrescope group, there was no significant difference in the intubation success rate and intubation times between the groups. There were a total of three failed intubations, two from the conventional fibrescope group and one from the aScope 2 group. One of the failed intubations in the fibrescope group was due to light source failure.
There were no significant differences in most subjective endpoints, including ease of setup, manoeuvrability, railroading and image quality. The operators found it significantly easier to use the aScope 2 compared to the fibrescope. A trend towards better image quality and railroading was noted in the fibrescope group; however, this was not statistically significant (Table 3) .
Multinomial logistical regressions involving each predictor (with scope type as a covariate) failed to identify any significant relationships between predictor and primary outcome of interest (GRS). Specific analysis was performed (within each scope type independently) looking at correlations between aScope 2 experience and specific endpoints (GRSs, T1, T2, ease of use, ease of setup, ease of railroading, image quality). Within the aScope 2 group, Pearson correlations identified significant negative correlations between aScope 2 experience and T1 (r=-0.56, 
Discussion
This is a study using the GRSs as the primary outcome to compare the aScope 2 and the fibrescope in the clinical setting. Time to intubation was commonly used as the primary outcome in other studies 10 . However, it was found to have no correlation with clinical performance in bronchoscopic efficacy 11 . The GRSs is a validated scoring system for clinical bronchoscopy used to benchmark operators 8, 9 . This study showed that there was no significant difference between the aScope 2 and the fibrescope in GRSs when performing fibreoptic intubation in anaesthetised patients. This finding was supported by Vijayakumar et al's result 7 which found no difference in the number of fibrescope tip collision counts during intubation between the aScope and Olympus fibrescope.
In contrast to Schoettker et al's study 10 , we would support the use of the aScope 2 as an alternative to the conventional reusable fibrescope, because of the comparable clinical performance as shown in this study. Schoettker et al found that using the aScope 2 resulted in a longer intubation time. However, in our study, we did not find any significant difference in GRSs, intubation time or intubation success between the two scopes. In fact, we found that the aScope 2 was rated as an easier to use device with fewer intubation attempts compared to the fibrescope.
The main difference between our study and Schoettker et al's study was that there was only one unblinded operator who performed all of the intubations in their study. This could lead to bias in their results. Moreover, we found that there was a significant negative correlation between previous aScope 2 experience and intubation time. This suggests a potential "learning effect", which would be expected to be present in the use of any new device found on the market 12 . A learning effect is suggested when there is an improvement in performance after using a new piece of equipment, when the procedure is already familiar to the operator. Our study involved eight experienced operators and the data analysis, including the GRSs and intubation times, were performed by two independent blinded observers. We believe that these measures should lead to a less biased result.
Although the aScope 2 had a slightly lower score in ease of railroading and image quality, it was still rated as the significantly easier to use device compared with the fibrescope. It was quick to set up and lightweight to hold.
Being quick to set up is of benefit in an emergency airway scenario where direct or video laryngoscopy has failed and a fibrescope is summoned 13 . Being more lightweight makes it easier to hold during prolonged intubations. Lack of a suction port has been highlighted in previous studies 10 , but the problem of secretions obscuring vision was overcome in our study by the use of an antisialogogue and the flow of oxygen through the insufflation port of the aScope 2.
Strengths of this study would include the comparable patient and operator characteristics. All of our eight operators were familiar with both devices and had comparable fibreoptic skills. Our major outcome measures were well-defined and objective. The assessment of GRSs and intubation times were performed by blinded observers using the videoclips, therefore minimising the risk of reporting bias.
Limitations of this study included the use of small sample size, which might have led to a potentially underpowered study to detect significant differences in our secondary outcomes. We did not study the device in awake intubations, but this has been addressed by another randomised controlled trial which used the aScope for awake fibreoptic intubations 14 . Kristensen and Fredensborg's study confirmed safe use of the aScope in awake intubations in patients with difficult airways, although the caveat remained that this only applied in an elective setting with skilled operators and in patients with severely difficult but uncompromised airways.
There was a potential for bias due to the use of antisialogogue in our study, which was not used in Schoettker et al's study 10 , but was used in Kristensen and Fredensborg's study 14 . One of the major criticisms of the aScope 2 was that it did not cope well with secretions due to the lack of a suction channel. By using glycopyrrolate in this study, it was possible that we might have biased the study in favour of the aScope 2. It is also important to highlight that the use of oxygen insufflation down the aScope 2 or bronchoscope is potentially dangerous due to the possibility of barotrauma should gas not be allowed to escape from a non-patent airway 15 . We chose this method of providing supplemental oxygenation as this was the usual practice within the department and the anaesthetists were mindful of maintaining airway patency at all times and only using very low oxygen flows.
Cost analysis comparing traditional fibrescopes and the aScope 2 has concluded that costs are approximately the same in a department performing a high volume of fibreoptic intubations. However, in departments that perform the occasional fibreoptic intubation, costs associated with the use of the aScope 2 may be lower 16 . As development of technology dictates, progression has rapidly led to the aScope 3 and aScope 3 slim 17 . Both aScope 3 versions have a number of improvements which focus on bettering the quality of vision and manoeuvrability of the scope, and a suction port is now available-addressing the deficiencies of the previous versions. The aScope 3 and aScope 3 slim have insertion cord diameters of 5.0 mm and 3.8 mm respectively. They both now incorporate working channels of 2.2 mm (aScope 3) and 1.2 mm (aScope 3 slim). Quality of vision is improved largely due to a new monitorthe Ambu aView which is capable of delivering 800 × 480 resolution, compared with the previous aScope monitor which only delivered 640 × 480 resolution.
National Institute for Health and Care Excellence guidelines in the UK have been released which support our findings, in which the aScope 2 is an acceptable alternative to the reusable fibrescope 17 . The National Audit Program Four guidelines have highlighted the increased frequency of harm to patients from underutilisation of available fibreoptic techniques 18 , hence improving the design to make fibreoptic equipment more user-friendly is beneficial. Equally important is promoting the skill of fibreoptic intubation during training, which can be facilitated by having access to an easily operated device.
Conclusion
Our study indicated that the aScope 2 showed a similar clinical profile to the Karl Storz fibreoptic bronchoscope, in well-prepared anaesthetised patients undergoing elective fibreoptic intubation. This device has been improved in recent times to its current version-the aScope 3. It is a relatively easy to use device. Its practicality and disposability potentially make it an acceptable alternative to the reusable fibrescope.
